| Completed | Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection NCT06945432 | Lanzhou University Second Hospital | — |
| Recruiting | HP Pyruvate MRI in Cancers NCT05697406 | University of Maryland, Baltimore | Phase 1 / Phase 2 |
| Unknown | A Novel 68Ga Labeled FAP Ligand PET/CT in Patients With Various Malignant Tumors NCT06186427 | Guangdong Provincial People's Hospital | N/A |
| Withdrawn | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tum NCT05431582 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | POWER UP: Participating Online While Exercising to Recover Using Play NCT05308407 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in T NCT05103358 | Aadi Bioscience, Inc. | Phase 2 |
| Recruiting | Cohort of Tumors With POLE/D1 Mutation NCT05103969 | Federation Francophone de Cancerologie Digestive | — |
| Recruiting | XACT ACE Observational Registry NCT04950959 | Xact Robotics Ltd. | — |
| Completed | Research on the Application and Mechanism of New Biological Probes in Biomedicine NCT04977739 | Nanfang Hospital, Southern Medical University | — |
| Completed | CDK4/6 Tumor, Abemaciclib, Paclitaxel NCT04594005 | Yonsei University | Phase 1 / Phase 2 |
| Recruiting | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling NCT04341181 | Ulrik Lassen | Phase 2 |
| Completed | A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Ma NCT03760081 | Astellas Pharma Global Development, Inc. | Phase 2 |
| Recruiting | Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base NCT05733091 | M.D. Anderson Cancer Center | — |
| Terminated | A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivo NCT03251924 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Terminated | Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs NCT02943733 | University of Wisconsin, Madison | Phase 1 |
| Terminated | Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer NCT03096340 | Intezyne Technologies, Inc. | Phase 1 |
| Unknown | Assay Development for Cancer Biomarkers NCT02874729 | King's College London | — |
| Recruiting | The Drug Rediscovery Protocol (DRUP Trial) NCT02925234 | The Netherlands Cancer Institute | Phase 2 |
| Completed | Point of Care 3D Ultrasound for Various Applications: A Pilot Study NCT02831556 | Duke University | — |
| Completed | Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects W NCT02686164 | Eisai Inc. | Phase 1 |
| Completed | A Phase I Study of PLX038 in Patients With Advanced Solid Tumors NCT02646852 | ProLynx LLC | Phase 1 |
| Completed | A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors NCT02549937 | Hutchmed | Phase 1 / Phase 2 |
| Completed | Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone NCT02532634 | Kangdong Sacred Heart Hospital | Phase 4 |
| Terminated | Study of E7046 in Subjects With Selected Advanced Malignancies NCT02540291 | Eisai Inc. | Phase 1 |
| Completed | A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors NCT02501096 | Eisai Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Atezolizumab in Advanced Solid Tumors NCT02458638 | Hoffmann-La Roche | Phase 2 |
| Terminated | Safety Study of AMG 228 to Treat Solid Tumors NCT02437916 | Amgen | Phase 1 |
| Unknown | Data Collection in Patients Undergoing CT-Guided Needle Interventions for NeedleWays System Development NCT02329665 | NeedleWays | N/A |
| Withdrawn | Ph Ib/BGJ398/Cervix and Other Solid Tumors NCT02312804 | The University of Texas Health Science Center at San Antonio | Phase 1 |
| Completed | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adult NCT02432274 | Eisai Limited | Phase 1 / Phase 2 |
| Completed | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma NCT02110355 | Kartos Therapeutics, Inc. | Phase 1 |
| Unknown | Detection of Tumor DNA in Blood Samples From Cancer Patients NCT02288754 | Lexent Bio, Inc. | — |
| Completed | Phase 1 Study of E7090 in Subjects With Solid Tumor NCT02275910 | Eisai Co., Ltd. | Phase 1 |
| Terminated | to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage NCT02271516 | National Atomic Research Institute, Taiwan | Phase 1 |
| Active Not Recruiting | Perioperative Risk Study NCT02456389 | Fox Chase Cancer Center | N/A |
| Completed | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With NCT01962103 | Celgene | Phase 1 / Phase 2 |
| Completed | Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors NCT01985555 | Hutchison Medipharma Limited | Phase 1 |
| Unknown | Biomarker Breast Pap Test NCT01683305 | Silbiotech | — |
| Completed | Phase I Study of LB-100 With Docetaxel in Solid Tumors NCT01837667 | Lixte Biotechnology Holdings, Inc. | Phase 1 |
| Completed | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma NCT01723020 | Kartos Therapeutics, Inc. | Phase 1 |
| Suspended | Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors NCT01562626 | Anaeropharma Science, Inc. | Phase 1 / Phase 2 |
| Completed | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuxim NCT01609556 | ImmunoGen, Inc. | Phase 1 |
| Withdrawn | A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies NCT01567384 | Emory University | Phase 1 |
| Unknown | Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics NCT02441972 | Wuxi No. 4 People's Hospital | Phase 1 |
| Completed | Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel NCT01448759 | Institut Curie | N/A |
| Completed | A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express N NCT01409135 | Astellas Pharma Inc | Phase 1 |
| Completed | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tol NCT01375842 | Genentech, Inc. | Phase 1 |
| Completed | AMG 319 Lymphoid Malignancy FIH NCT01300026 | Amgen | Phase 1 |
| Completed | MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies NCT01235897 | University of California, San Francisco | Phase 1 |
| Completed | Kypho-IORT: Intraoperative Radiotherapy During Kyphoplasty for Spinal Metastases NCT01280032 | Universitätsmedizin Mannheim | Phase 2 |
| Completed | A Study of AMG 337 in Subjects With Advanced Solid Tumors NCT01253707 | Amgen | Phase 1 |
| Completed | Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced S NCT01155713 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Comparison of the Cosmetic Outcome of Hypofractionated Versus Normofractionated IMRT in Treatment of Breast Ca NCT01403779 | Universitätsmedizin Mannheim | Phase 3 |
| Unknown | 18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology NCT01180751 | University of Manitoba | Phase 3 |
| Completed | Proton Radiotherapy for Recurrent Tumors NCT01126476 | Abramson Cancer Center at Penn Medicine | N/A |
| Completed | Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced NCT01030055 | Novartis Pharmaceuticals | Phase 1 |
| Withdrawn | ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors NCT01031212 | University of California, San Francisco | Phase 1 |
| Completed | A Study of IMC-A12 in Advanced Solid Tumors NCT01007032 | Eli Lilly and Company | Phase 1 |
| Terminated | Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid T NCT01081808 | Roger Williams Medical Center | Phase 1 |
| Completed | A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors NCT00858377 | Amgen | Phase 1 |
| Completed | Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid NCT00960258 | Bayer | Phase 1 |
| Completed | Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Panc NCT00830778 | Baki Topal | Phase 3 |
| Completed | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer NCT00807859 | Amgen | Phase 1 |
| Completed | Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination NCT00821652 | Nina Bhardwaj | Phase 1 |
| Completed | Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prosta NCT00838201 | Amgen | Phase 3 |
| Completed | A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED) NCT00800865 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial O NCT00770536 | Amgen | Phase 1 |
| Completed | A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors NCT00813384 | Amgen | Phase 1 |
| Completed | A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced NCT00728793 | Curis, Inc. | Phase 1 |
| Completed | Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Health NCT00777530 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | A Study of AMG 820 in Subjects With Advanced Solid Tumors NCT01444404 | AmMax Bio, Inc. | Phase 1 |
| Completed | A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer NCT00653939 | Mateon Therapeutics | Phase 2 |
| Completed | A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Pa NCT00613652 | AstraZeneca | Phase 1 |
| Completed | Optimal Application Dose of Superficial Hyperthermia NCT00766233 | Universitätsmedizin Mannheim | Phase 3 |
| Completed | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) NCT00446446 | Amgen | Phase 2 |
| Completed | A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Do NCT00435669 | Bristol-Myers Squibb | Phase 1 |
| Completed | A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced S NCT00495144 | Threshold Pharmaceuticals | Phase 1 |
| Completed | An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Othe NCT00514267 | Astellas Pharma Inc | Phase 1 / Phase 2 |
| Terminated | Study of Satraplatin (JM-216) in Combination With Docetaxel NCT00125411 | Agennix | Phase 1 |
| Completed | A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumor NCT00422682 | Sanofi | Phase 1 |
| Completed | Study of Dasatinib (BMS-354825) in Patients With Solid Tumors NCT00339144 | Bristol-Myers Squibb | Phase 1 |
| Terminated | Dose Escalation Study of SH U04722 in Solid Tumors NCT00375453 | Bayer | Phase 1 |
| Completed | QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors NCT00974896 | NantCell, Inc. | Phase 1 |
| Completed | Oral Topotecan to Treat Recurrent or Persistent Solid Tumors NCT00382733 | Accelerated Community Oncology Research Network | Phase 1 / Phase 2 |
| Completed | LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma NCT00412997 | Novartis | Phase 1 |
| Completed | A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid NCT00397046 | Puma Biotechnology, Inc. | Phase 1 |
| Completed | Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies NCT00389480 | Arno Therapeutics | Phase 1 |
| Completed | Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers NCT00398814 | AEterna Zentaris | Phase 1 |
| Completed | Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With NCT00395434 | Mateon Therapeutics | Phase 1 |
| Completed | Rapamycin With Grapefruit Juice for Advanced Malignancies NCT00375245 | University of Chicago | Phase 1 |
| Completed | Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy NCT00410696 | Armando Santoro, MD | Phase 2 |
| Completed | A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced NCT00400023 | Taiho Oncology, Inc. | Phase 1 |
| Completed | A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine NCT00372437 | Mirati Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan NCT00412789 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy NCT00358397 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Diseas NCT00364676 | Spectrum Pharmaceuticals, Inc | Phase 1 |
| Terminated | A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma NCT00363610 | Enzon Pharmaceuticals, Inc. | Phase 1 |
| Completed | A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) NCT00373490 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Child NCT00607984 | Rabin Medical Center | N/A |
| Completed | A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours NCT02182128 | Boehringer Ingelheim | Phase 1 |
| Completed | AZD1152 in Patients With Advanced Solid Malignancies NCT00338182 | AstraZeneca | Phase 1 |
| Completed | A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function NCT00421044 | Novartis Pharmaceuticals | Phase 1 |
| Completed | NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors NCT00299728 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Su NCT00298675 | Sanofi | Phase 1 |
| Terminated | A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel NCT00313456 | Agennix | Phase 1 |
| Completed | Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors NCT00345189 | Biogen | Phase 1 |
| Completed | Study Evaluating SKI-606 in Subject With Solid Tumors NCT01001936 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Terminated | Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard NCT00402415 | Yale University | Phase 1 |
| Completed | A Phase I Study of ECO-4601 in Patients With Advanced Cancer NCT00338026 | Thallion Pharmaceuticals | Phase 1 |
| Completed | Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors NCT00292864 | Sunesis Pharmaceuticals | Phase 1 |
| Completed | A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function NCT00420524 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | Study of BMS-663513 in Patients With Advanced Cancer NCT00309023 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | A Phase I Study of G3139 Subcutaneous in Solid Tumors NCT00543231 | Genta Incorporated | Phase 1 |
| Completed | Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tu NCT00264004 | AstraZeneca | Phase 2 |
| Terminated | INNO-105 in Patients With Solid Tumors NCT00255333 | Innovive Pharmaceuticals | Phase 1 |
| Terminated | Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatm NCT00130936 | AHS Cancer Control Alberta | Phase 1 / Phase 2 |
| Unknown | Laparoscopic Liver Resection NCT00553033 | IRCCS San Raffaele | — |
| Completed | NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) NCT00248404 | Kiadis Pharma | Phase 1 / Phase 2 |
| Terminated | Study Evaluating TTI-237 in Advanced Malignant Solid Tumors. NCT00195325 | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Terminated | Study of Dasatinib in Patients With Advanced Solid Tumors NCT00162214 | Bristol-Myers Squibb | Phase 1 |
| Completed | Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent NCT00127829 | AstraZeneca | Phase 1 |
| Completed | A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) NCT00127127 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies NCT00129337 | Peregrine Pharmaceuticals | Phase 1 |
| Terminated | Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown P NCT00201734 | Ohio State University Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas NCT00389077 | AEterna Zentaris | Phase 2 |
| Terminated | Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors NCT00105170 | Biogen | Phase 1 |
| Terminated | Rare Tumor Case Review NCT00229879 | Children's Healthcare of Atlanta | — |
| Completed | Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors NCT00187174 | St. Jude Children's Research Hospital | Phase 1 |
| Terminated | A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies NCT00207025 | Bristol-Myers Squibb | Phase 1 |
| Completed | Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Re NCT00222443 | University of Oklahoma | Phase 1 |
| Completed | MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors NCT00207103 | Bristol-Myers Squibb | Phase 1 |
| Completed | Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors NCT00091806 | Amgen | Phase 1 |
| Completed | Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00323934 | Mirati Therapeutics Inc. | Phase 1 |
| Completed | Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patie NCT00230217 | Sanofi | Phase 4 |
| Terminated | Safety of CHIR-258 (TKI258) in Advanced Solid Tumors NCT01270906 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors NCT00093873 | Amgen | Phase 1 |
| Completed | An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours NCT02182206 | Boehringer Ingelheim | Phase 1 |
| Completed | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) NCT00060645 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5 NCT00060632 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With C NCT00171587 | Novartis | Phase 1 / Phase 2 |
| Completed | Expression of NIS Protein and mRNA in Thyroid Tumors NCT00459498 | University of Sao Paulo | — |
| Completed | Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer NCT00024492 | INSYS Therapeutics Inc | Phase 1 |
| Completed | Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction NCT00113113 | Astex Pharmaceuticals, Inc. | Phase 1 |
| Completed | Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors NCT00201812 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Completed | A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664) NCT00437437 | Bristol-Myers Squibb | Phase 1 |
| Completed | Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) NCT00179764 | Ann & Robert H Lurie Children's Hospital of Chicago | N/A |
| Unknown | Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for NCT00149006 | Hadassah Medical Organization | Phase 2 |
| Unknown | Ultrasonic Evaluation of Ocular Tissues NCT00279695 | Weill Medical College of Cornell University | — |
| Terminated | Comparing Magnetic Resonance Imaging/Spectroscopy Techniques NCT00001219 | National Institutes of Health Clinical Center (CC) | — |
| Completed | Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either NCT00298779 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When U NCT00129207 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Withdrawn | A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies NCT00162500 | Hadassah Medical Organization | Phase 2 |
| Withdrawn | GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers NCT01437280 | Baylor College of Medicine | Phase 1 |
| Completed | Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors NCT00102830 | Amgen | Phase 1 |